Advances in Microfluidic‐Based Core@Shell Nanoparticles Fabrication for Cancer Applications

Author:

Almeida Duarte R. S.12,Gil João Ferreira12,Guillot Antonio José34,Li Jiachen4,Pinto Ricardo J. B.5ORCID,Santos Hélder A.46ORCID,Gonçalves Gil12

Affiliation:

1. Centre for Mechanical Technology and Automation (TEMA) Mechanical Engineering Department University of Aveiro Aveiro 3810‐193 Portugal

2. Intelligent Systems Associate Laboratory (LASI) Guimarães 4800‐058 Portugal

3. Department of Pharmacy and Pharmaceutical Technology and Parasitology University of Valencia Ave. Vicent Andrés Estellés s/n Burjassot Valencia 46100 Spain

4. Department of Biomaterials and Biomedical Technology University Medical Center Groningen (UMCG) University of Groningen Groningen 9713 AV The Netherlands

5. CICECO—Aveiro Institute of Materials Chemistry Department University of Aveiro Aveiro 3810‐193 Portugal

6. Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki Helsinki 00014 Finland

Abstract

AbstractCurrent research in cancer therapy focuses on personalized therapies, through nanotechnology‐based targeted drug delivery systems. Particularly, controlled drug release with nanoparticles (NPs) can be designed to safely transport various active agents, optimizing delivery to specific organs and tumors, minimizing side effects. The use of microfluidics (MFs) in this field has stood out against conventional methods by allowing precise control over parameters like size, structure, composition, and mechanical/biological properties of nanoscale carriers. This review compiles applications of microfluidics in the production of core‐shell NPs (CSNPs) for cancer therapy, discussing the versatility inherent in various microchannel and/or micromixer setups and showcasing how these setups can be utilized individually or in combination, as well as how this technology allows the development of new advances in more efficient and controlled fabrication of core‐shell nanoformulations. Recent biological studies have achieved an effective, safe, and controlled delivery of otherwise unreliable encapsulants such as small interfering RNA (siRNA), plasmid DNA (pDNA), and cisplatin as a result of precisely tuned fabrication of nanocarriers, showing that this technology is paving the way for innovative strategies in cancer therapy nanofabrication, characterized by continuous production and high reproducibility. Finally, this review analyzes the technical, biological, and technological limitations that currently prevent this technology from becoming the standard.

Funder

Fundação para a Ciência e a Tecnologia

Publisher

Wiley

Reference184 articles.

1. Global Cancer Observatory “Cancer Today ”2023. (accessed: July 2023).

2. American Cancer Society2007. (accessed: July 2023).

3. Remotely Activated Nanoparticles for Anticancer Therapy

4. A Recent Review on Cancer Nanomedicine

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3